1. Jul 2026
Description
(AWP Alliance News) - Lonza expanded a strategic collaboration with a leading US biopharmaceutical company, adding two biologics programs for commercial production with options for two more. The long-term set of contracts has the potential to deliver a multi-billion cumulative CHF value.
Work will be supplied from Lonza's US commercial-scale biologics network, supported by drug substance and drug product capabilities in Europe. The partnership includes process intensification such as N-1 perfusion, manufacturing process optimization to cut cycle times, and drug product manufacturing to support end-to-end delivery.
https://www.publicnow.com/view/ADC86B70D587591641019470CD7D8F92EE2E8B6F…
Disclaimer: This news brief was created using generative artificial intelligence. Lonza Group Ltd. published the original content used to generate this news brief via EQS News on July 01, 2026, and is solely responsible for the information contained therein.
